{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:21:31Z","timestamp":1773159691016,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in North America. Previous studies have shown improved progression free survival (PFS) and response rates in unfit patients treated with obinutuzumab compared to other regimens. The aim of this study was to evaluate the obinutuzumab-chlorambucil regimen in the context of historical treatments and first-dose infusion reactions at CancerCare Manitoba (CCMB).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective chart review was conducted for patients treated with obinutuzumab from January 1, 2014 to December 31, 2017 at CCMB. A minimum data set was extracted for patients treated with other front-line therapies. Descriptive statistics were used to evaluate patient demographics, toxicity, duration and dosing of obinutuzumab treatment. Kaplan\u2013Meier curves were used to evaluate time-to-next-treatment (TTNT), overall survival (OS) and PFS for patients treated with obinutuzumab. A multivariable logistic regression model was used to investigate associations between infusion related reactions (IRRs) and age at treatment, pre-treatment lymphocyte count, cumulative illness rating scale (CIRS) and receipt of prior chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty seven percent of patients receiving frontline therapy received chlorambucil and obinutuzumab. Sixty-seven patients were treated with obinutuzumab and consisted of 36 males (53.7%) and 31 females (46.3%) with 29 patients (43.3%) over age 75\u00a0years. Rates of grade 3 and 4 obinutuzumab IRRs were lower (6%) compared to the CLL11 clinical trial (20%) due to local practices including slower infusion rates and using chlorambucil before starting obinutuzumab treatment. Many patients had difficulty tolerating the full dosage of chlorambucil. Only 26 patients (38.8%) had their dose of chlorambucil escalated to the full dose of 0.5\u00a0mg\/kg. In addition, only 18 patients (26.9%) received all doses of obinutuzumab and all 12 doses of chlorambucil.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In summary, first dose infusion reactions with obinutuzumab can be markedly reduced by using chlorambucil to decrease the lymphocyte count before obinutuzumab and by using a very slow initial obinutuzumab infusion rate. Modifications in chlorambucil dosing and obinutuzumab administration can improve tolerance without significant loss in efficacy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09256-2","type":"journal-article","created":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T02:02:12Z","timestamp":1644112932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia"],"prefix":"10.1186","volume":"22","author":[{"given":"Nicole","family":"Bourrier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Landego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Squires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Streu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Hibbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Whiteside","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer B.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Geirnaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Dawe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Versha","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,6]]},"reference":[{"issue":"1","key":"9256_CR1","first-page":"9","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. A Cancer J Clin. 2020;70(1):9.","journal-title":"A Cancer J Clin"},{"key":"9256_CR2","unstructured":"Statistics Canada. Population estimates, quarterly [Internet]. 2019 [cited 2019 Aug 16]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710000901"},{"key":"9256_CR3","unstructured":"Department of Epidemiology and Cancer Registry. Cancer in Manitoba 2016 Annual Statistical Report [Internet]. CancerCare Manitoba. 2016 [cited 2021 Jun 10]. p. 7. Available from: https:\/\/www.cancercare.mb.ca\/export\/sites\/default\/.galleries\/files\/Cancer-in-Manitoba-2016-Annual-Statistical-Report.pdf"},{"key":"9256_CR4","doi-asserted-by":"crossref","unstructured":"Hallek M. Chronic lymphocytic leukemia:2019 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266-87.","DOI":"10.1002\/ajh.25595"},{"issue":"6","key":"9256_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/cam4.559","volume":"5","author":"S Beiggi","year":"2016","unstructured":"Beiggi S, Banerji V, Deneka A, Griffith J, Gibson SB, Johnston JB. Comparison of outcome of patients with CLL who are referred or nonreferred to a specialized CLL clinic: a Canadian population-based study. Cancer Med. 2016;5(6):971\u20139.","journal-title":"Cancer Med"},{"issue":"7\u20138","key":"9256_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.20452\/pamw.4326","volume":"128","author":"V Goede","year":"2018","unstructured":"Goede V. Frontline treatment of chronic lymphocytic leukemia with obinutuzumab and chlorambucil how does it work in \u201creal-life\u201d? Polish Arch Intern Med. 2018;128(7\u20138):414\u20135.","journal-title":"Polish Arch Intern Med"},{"key":"9256_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imj.13493","volume":"47","author":"C Tam","year":"2017","unstructured":"Tam C, Kuss B, Opat S, Boulos J, Marlton P. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil. Intern Med J. 2017;47:5\u201310.","journal-title":"Intern Med J"},{"issue":"7","key":"9256_CR8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet. 2016;17(7):928\u201342.","journal-title":"Lancet"},{"issue":"12","key":"9256_CR9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"15","key":"9256_CR10","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","volume":"119","author":"J Honeychurch","year":"2012","unstructured":"Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012;119(15):3523\u201333.","journal-title":"Blood"},{"issue":"2","key":"9256_CR11","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.1188\/16.CJON.E41-E48","volume":"20","author":"K Dawson","year":"2016","unstructured":"Dawson K, Moran M, Guindon K, Wan H. Managing infusion-related reactions for patients with chronic lymphocytic leukemia receiving obinutuzumab. Clin J Oncol Nurs. 2016;20(2):E41.","journal-title":"Clin J Oncol Nurs"},{"key":"9256_CR12","unstructured":"LaCasce AS, Castells MC, Burstein HJ, Meyerhardt JA. Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy. In: UptoDate [Internet]. 2019. Available from: https:\/\/www-uptodate-com.uml.idm.oclc.org\/contents\/infusion-related-reactions-to-therapeutic-monoclonal-antibodies-used-for-cancer-therapy?search=infusion related reactions grading&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2"},{"issue":"25","key":"9256_CR13","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"key":"9256_CR14","unstructured":"Pan-Canadian Oncology Drug Review. Provincial Funding Summary Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia. 2018. p. 1\u20134."},{"key":"9256_CR15","unstructured":"CancerCare Manitoba. Regimen Reference Order - CLL- oBINutuzumab + chlorambucil. 2018. p. 1\u20134."},{"issue":"7\u20138","key":"9256_CR16","first-page":"421","volume":"128","author":"M D\u0142ugosz-Danecka","year":"2018","unstructured":"D\u0142ugosz-Danecka M, Jurczak W, \u0141\u0105tka-Caba\u0142a E, Morawska M, Gawro\u0144ski K, Wi\u015bniewska A, et al. Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities-Polish Adult Leukemia Group (PALG) real-life analysis. Polish Arch Intern Med. 2018;128(7\u20138):421\u20136.","journal-title":"Polish Arch Intern Med"},{"issue":"10","key":"9256_CR17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.leukres.2015.07.009","volume":"39","author":"L Laurenti","year":"2015","unstructured":"Laurenti L, Innocenti I, Autore F, Vannata B, Efremov DG, Ciolli S, et al. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. Leuk Res. 2015;39(10):1066\u201370.","journal-title":"Leuk Res"},{"issue":"9747","key":"9256_CR18","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomized, open-label, phase 3 trial. Lancet. 2010;376(9747):1164\u201374.","journal-title":"Lancet"},{"issue":"1","key":"9256_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","volume":"105","author":"JC Byrd","year":"2005","unstructured":"Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49\u201353.","journal-title":"Blood"},{"issue":"12","key":"9256_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Protocol for: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"5","key":"9256_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/hon.2684","volume":"37","author":"F Autore","year":"2019","unstructured":"Autore F, Fresa A, Innocenti I, Tomasso A, Morelli F, Corbingi A, et al. Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience. Hematol Oncol. 2019;37(5):641\u20133.","journal-title":"Hematol Oncol"},{"issue":"1","key":"9256_CR22","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.3324\/haematol.2018.212597","volume":"105","author":"JV Lujan","year":"2020","unstructured":"Lujan JV, Lengerke-Diaz PA, Jacobs C, Moreno-Cortes EF, Ramirez-Segura CA, Choi MY, et al. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2020;105(1):e22.","journal-title":"Haematologica"},{"key":"9256_CR23","first-page":"215923","volume":"15","author":"V Goede","year":"2018","unstructured":"Goede V, Fischer K, Dyer MJ, M\u00fcller L, Smolej L, Di Bernardo MC, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic and comorbidities: final survival analysis of the CLL11 study. EHA Learn Cent. 2018;15:215923.","journal-title":"EHA Learn Cent"},{"issue":"4","key":"9256_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/hon.2744","volume":"38","author":"A Panovsk\u00e1","year":"2020","unstructured":"Panovsk\u00e1 A, N\u011bmcov\u00e1 L, Nekvindov\u00e1 L, \u0160pa\u010dek M, \u0160imkovi\u010d M, Papaj\u00edk T, et al. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group. Hematol Oncol. 2020;38(4):509\u201316.","journal-title":"Hematol Oncol"},{"issue":"6","key":"9256_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25766","volume":"95","author":"Y Herishanu","year":"2020","unstructured":"Herishanu Y, Shaulov A, Fineman R, Ba\u0161i\u0107-Kinda S, Aviv A, Wasik-Szczepanek E, et al. Frontline treatment with the combination obinutuzumab \u00b1 chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. Am J Hematol. 2020;95(6):604\u201311.","journal-title":"Am J Hematol"},{"issue":"23","key":"9256_CR26","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225\u201336.","journal-title":"N Engl J Med."},{"issue":"1","key":"9256_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1182\/blood-2015-03-634394","volume":"127","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016;127(1):79\u201386.","journal-title":"Blood"},{"issue":"4","key":"9256_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1080\/10428194.2018.1515940","volume":"60","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, et al. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leuk Lymphoma. 2019;60(4):894\u2013903.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"9256_CR29","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jjco\/hyy087","volume":"48","author":"K Ohmachi","year":"2018","unstructured":"Ohmachi K, Ando K, Kinoshita T, Kumagai K, Hatake K, Ishikawa T, et al. Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study. Jpn J Clin Oncol. 2018;48(8):736\u201342.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"9256_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, Greil PR, Demirkan PF, Tedeschi A, Anz B, Larratt PL, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2019;20(1):43\u201356.","journal-title":"Lancet"},{"issue":"10129","key":"9256_CR31","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524\u201337.","journal-title":"Lancet"},{"issue":"10232","key":"9256_CR32","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278\u201391.","journal-title":"Lancet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09256-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T14:02:45Z","timestamp":1644156165000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09256-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9256"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09256-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,6]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed according to the World Medical Association\u2019s declaration of Helsinki (6<sup>th<\/sup> version, Seoul, South Korea, 2008) and authorized by the University of Manitoba\u2019s Human Research Ethics Board (approval HS20766).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests with respect to this project.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}